Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10

Charles A. Butts, Keyue Ding, Lesley Seymour, Philip Twumasi-Ankrah, Barbara Graham, David Gandara, David H. Johnson, Kenneth A. Kesler, Mark Green, Mark Vincent, Yvon Cormier, Glenwood Goss, Brian Findlay, Michael Johnston, Ming Sound Tsao, Frances A. Shepherd

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Survival Analysis
Non-Small Cell Lung Carcinoma
Cisplatin
Observation
Drug Therapy
Survival
Cause of Death
Second Primary Neoplasms
Lost to Follow-Up
Adjuvant Chemotherapy
Lung Neoplasms
vinorelbine
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer : Updated survival analysis of JBR-10. / Butts, Charles A.; Ding, Keyue; Seymour, Lesley; Twumasi-Ankrah, Philip; Graham, Barbara; Gandara, David; Johnson, David H.; Kesler, Kenneth A.; Green, Mark; Vincent, Mark; Cormier, Yvon; Goss, Glenwood; Findlay, Brian; Johnston, Michael; Tsao, Ming Sound; Shepherd, Frances A.

In: Journal of Clinical Oncology, Vol. 28, No. 1, 01.01.2010, p. 29-34.

Research output: Contribution to journalArticle

Butts, CA, Ding, K, Seymour, L, Twumasi-Ankrah, P, Graham, B, Gandara, D, Johnson, DH, Kesler, KA, Green, M, Vincent, M, Cormier, Y, Goss, G, Findlay, B, Johnston, M, Tsao, MS & Shepherd, FA 2010, 'Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10', Journal of Clinical Oncology, vol. 28, no. 1, pp. 29-34. https://doi.org/10.1200/JCO.2009.24.0333
Butts, Charles A. ; Ding, Keyue ; Seymour, Lesley ; Twumasi-Ankrah, Philip ; Graham, Barbara ; Gandara, David ; Johnson, David H. ; Kesler, Kenneth A. ; Green, Mark ; Vincent, Mark ; Cormier, Yvon ; Goss, Glenwood ; Findlay, Brian ; Johnston, Michael ; Tsao, Ming Sound ; Shepherd, Frances A. / Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer : Updated survival analysis of JBR-10. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 1. pp. 29-34.
@article{bce54ac295044da7b9da68a6995e0cf6,
title = "Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10",
abstract = "Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95{\%} CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95{\%} CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95{\%} CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95{\%} CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.",
author = "Butts, {Charles A.} and Keyue Ding and Lesley Seymour and Philip Twumasi-Ankrah and Barbara Graham and David Gandara and Johnson, {David H.} and Kesler, {Kenneth A.} and Mark Green and Mark Vincent and Yvon Cormier and Glenwood Goss and Brian Findlay and Michael Johnston and Tsao, {Ming Sound} and Shepherd, {Frances A.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1200/JCO.2009.24.0333",
language = "English (US)",
volume = "28",
pages = "29--34",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer

T2 - Updated survival analysis of JBR-10

AU - Butts, Charles A.

AU - Ding, Keyue

AU - Seymour, Lesley

AU - Twumasi-Ankrah, Philip

AU - Graham, Barbara

AU - Gandara, David

AU - Johnson, David H.

AU - Kesler, Kenneth A.

AU - Green, Mark

AU - Vincent, Mark

AU - Cormier, Yvon

AU - Goss, Glenwood

AU - Findlay, Brian

AU - Johnston, Michael

AU - Tsao, Ming Sound

AU - Shepherd, Frances A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.

AB - Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.

UR - http://www.scopus.com/inward/record.url?scp=73949154000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949154000&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.24.0333

DO - 10.1200/JCO.2009.24.0333

M3 - Article

C2 - 19933915

AN - SCOPUS:73949154000

VL - 28

SP - 29

EP - 34

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -